Pyropheophorbide-a

CAT:
804-HY-128973-01
Size:
5 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Pyropheophorbide-a - image 1

Pyropheophorbide-a

  • UNSPSC Description:

    Pyropheophorbide-a (Ppa) is a photosensitizer used in photodynamic therapy (PDT) for tumors. Pyropheophorbide-a exhibits phototoxic effects on tumor cells, such as cervical cancer cells, and also has anti-lipogenesis activity. Pyropheophorbide-a shows potential for research in the fields of cancer and age-related macular degeneration (AMD). Pyropheophorbide-a derivatives also demonstrate inhibitory activity against tumor cells[1][2][3][4].
  • Target Antigen:

    Reactive Oxygen Species
  • Type:

    Reference compound
  • Related Pathways:

    Immunology/Inflammation;Metabolic Enzyme/Protease;NF-κB
  • Field of Research:

    Cancer
  • Assay Protocol:

    https://www.medchemexpress.com/pyropheophorbide-a.html
  • Purity:

    98.0
  • Solubility:

    DMSO : 12.5 mg/mL (ultrasonic)
  • Smiles:

    CC1=C2C(N/C1=C\3)=C(CC2=O)C([C@H]4CCC(O)=O)=N/C([C@H]4C)=C\C5=C(C)C(C=C)=C(N5)/C=C6C(C)=C(CC)C3=N/6
  • Molecular Weight:

    534.65
  • References & Citations:

    [1]Li W, et al. cRGD Peptide-Conjugated Pyropheophorbide-a Photosensitizers for Tumor Targeting in Photodynamic Therapy. Mol Pharm. 2018 Apr 2;15(4):1505-1514.|[2]Liu YH, et al. Anti-adipogenic activities of pheophorbide a and pyropheophorbide a isolated from wild bitter gourd (Momordica charantia L. var. abbreviata Seringe) in vitro. J Sci Food Agric. 2022 Nov;102(14):6771-6779.|[3]Bao L L, et al. In vitro and in vivo evaluation of a pyropheophorbide-a derivative as a potential photosensitizer for age-related macular degeneration[J]. Biomedicine & Pharmacotherapy, 2017, 88: 1220-1226.|[4]Chaturvedi P K, et al. Phototoxic effects of pyropheophorbide-a from chlorophyll-a on cervical cancer cells[J]. Journal of Porphyrins and Phthalocyanines, 2014, 18(03): 182-187.
  • Shipping Conditions:

    Room Temperature
  • Storage Conditions:

    4°C (Powder, protect from light)
  • Clinical Information:

    Phase 2
  • CAS Number:

    24533-72-0